The Children's Hospital of Philadelphia was awarded $38.9 million to advance gene‑editing therapies for hemophilia A and ...
Hemophilia is a blood disorder that is characterized by a shortage of specific clotting factors that help to form blood clots and stop bleeding. Historically, the primary treatment for hemophilia is ...
Factor VIII (FVIII) replacement therapy is a cornerstone of treatment for many people with hemophilia A, a rare bleeding disorder caused by deficient or dysfunctional FVIII, a protein needed for blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results